Crohn's disease

Kangpu Biopharmaceuticals to Present Preclinical Efficacy Data of KPG-818 in Crohn's Disease at the 19th Congress of ECCO (IND Application for Phase II in Progress)

Retrieved on: 
Tuesday, February 20, 2024

Crohn's disease is a chronic and difficult-to-treat autoimmune disorder.

Key Points: 
  • Crohn's disease is a chronic and difficult-to-treat autoimmune disorder.
  • The current available therapeutic options for this condition are very limited, and there remain significant unmet medical needs.
  • In preclinical studies, KPG-818 demonstrated potent therapeutic efficacy in mouse model of Crohn's disease.
  • Based on the recent Pre-IND meeting with the FDA, Kangpu Biopharmaceuticals will submit IND application for Phase II clinical trials of KPG-818 for Crohn's disease in the United States.

AbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO)

Retrieved on: 
Monday, February 19, 2024

NORTH CHICAGO, Ill., Feb. 19, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that 17 AbbVie-sponsored abstracts, including new data from its inflammatory bowel disease (IBD) portfolio, have been accepted for presentation at the 19th Congress of European Crohn's and Colitis Organisation (ECCO) taking place in Stockholm, Sweden from February 21-24.

Key Points: 
  • The research spans risankizumab (SKYRIZI®) and upadacitinib (RINVOQ®) in both Crohn's disease (CD) and ulcerative colitis (UC).
  • "Despite continued advancements, many patients are still suffering from the debilitating effects of living with IBD," said Sofie Berg, Pharm.D, Ph.D., therapeutic area head, international immunology, International Medical Affairs, AbbVie.
  • "It is critically important that as the treatment paradigm shifts, the gastroenterology community shifts with it.
  • SKYRIZI® (risankizumab) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

Takeda Supports the Canadian IBD Research Consortium's $1 Million Pioneer Grant for Second Year

Retrieved on: 
Tuesday, February 13, 2024

TORONTO, Feb. 13, 2024 /CNW/ - Takeda Canada Inc. (Takeda) is pleased to announce its support of the Canadian Inflammatory Bowel Disease Research Consortium's (CIRC) $1 million PIONEER Grant in its second year.

Key Points: 
  • TORONTO, Feb. 13, 2024 /CNW/ - Takeda Canada Inc. (Takeda) is pleased to announce its support of the Canadian Inflammatory Bowel Disease Research Consortium's (CIRC) $1 million PIONEER Grant in its second year.
  • This grant, with Takeda contributing $500,000 of the $1,000,000 award, will continue to support high-quality, impactful Canadian clinical research to improve patient outcomes and quality of life for people living with inflammatory bowel disease (IBD).
  • "We are immensely proud of our research community, this program and are grateful for Takeda partnership and dedication to advancing research in Canada."
  • "The PIONEER Grant, established through $1,000,000 in support from Takeda, gives Canadian IBD researchers an amazing and truly unique opportunity to conduct practice changing investigator-initiated research.

Bruce Sherman, Chairman and Principal Owner of the Miami Marlins, to Receive 2024 Horatio Alger Award

Retrieved on: 
Tuesday, February 6, 2024

WASHINGTON, Feb. 6, 2024 /PRNewswire/ -- Horatio Alger Association of Distinguished Americans, Inc., a nonprofit educational organization honoring the achievements of outstanding individuals and encouraging youth to pursue their dreams through higher education, today announced that Bruce S. Sherman, chairman and principal owner of the Miami Marlins, has been selected for membership in this prestigious organization. Mr. Sherman joins 10 other exceptional business, civic and cultural leaders from across North America in receiving 2024 honors. For more than 75 years, the Horatio Alger Award has been annually bestowed upon esteemed individuals who have succeeded despite facing adversities, and who have remained committed to higher education and charitable efforts in their communities. 

Key Points: 
  • In 2017, he became the chairman and principal owner of the Miami Marlins, a Major League Baseball team.
  • "It is our utmost honor to present the Horatio Alger Award to these 11 outstanding leaders who have exemplified perseverance, passion and a deep appreciation for higher education," said James F. Dicke II, chairman, Horatio Alger Association and 2015 Horatio Alger Award recipient.
  • Mr. Sherman and the Member Class of 2024 will be formally inducted into the Association on April 4-6, 2024, during the Association's annual Horatio Alger Award Induction Ceremonies in Washington, D.C.
  • For more information about Horatio Alger Association and its Member Class of 2024, please visit www.horatioalger.org and follow the organization on Facebook , X , LinkedIn and Instagram .

Boomerang Medical Awarded "Promising Up-and-Comer in the Fight Against Ulcerative Colitis and Crohn’s Disease" by the Crohn’s & Colitis Foundation

Retrieved on: 
Wednesday, January 31, 2024

Boomerang Medical, a women-led bioelectronic medicine company, received the Corporate Circle Award for "Promising Up-and-Comer in the Fight Against Ulcerative Colitis and Crohn’s Disease” from the Crohn's & Colitis Foundation.

Key Points: 
  • Boomerang Medical, a women-led bioelectronic medicine company, received the Corporate Circle Award for "Promising Up-and-Comer in the Fight Against Ulcerative Colitis and Crohn’s Disease” from the Crohn's & Colitis Foundation.
  • This award, given for the first time to a medical device company, acknowledges Boomerang Medical's alignment with the Foundation’s mission to improve the lives of those affected by inflammatory bowel disease.
  • The award was presented at the Foundation's annual President’s Corporate Circle reception, held during the annual Crohn’s & Colitis Congress® on January 26, 2024.
  • Heather Simonsen, CEO of Boomerang Medical, commented on the significance of this recognition: “We are deeply honored to be acknowledged by the Crohn’s & Colitis Foundation with this award.

KPMG in Canada reinforces employee and community commitment to People with Disabilities

Retrieved on: 
Wednesday, January 31, 2024

"The reality is, People with Disabilities still face physical, cultural, and attitudinal barriers in the Canadian workplace," says Rob Davis, Chief Inclusion, Diversity and Equity Officer, at KPMG in Canada.

Key Points: 
  • "The reality is, People with Disabilities still face physical, cultural, and attitudinal barriers in the Canadian workplace," says Rob Davis, Chief Inclusion, Diversity and Equity Officer, at KPMG in Canada.
  • As outlined in the plan, KPMG will create a Disability Inclusion Action Plan Steering Group to oversee the implementation of 40-plus actions and provide ongoing feedback.
  • People with Disabilities are an untapped pool of talent that could help Canada close the labour skills gap.
  • "Many with non-apparent disabilities hide them for fear of being stigmatized or hurting their chances of employment or promotion.

Nexus Search Partners Lands Amazon, Microsoft Vet to Join Burgeoning Executive Search Practice

Retrieved on: 
Tuesday, January 23, 2024

CHARLOTTE, N.C., Jan. 23, 2024 /PRNewswire-PRWeb/ -- Nexus Search Partners, a purpose-driven executive search and advisory firm that prioritizes inclusion, diversity and equity (ID&E) in the workplace, has announced that Sean Kelley, a former Amazon and Microsoft executive who pioneered the development of inclusive talent strategies and military veteran transition programs, will join Nexus as a senior partner. His nationally recognized expertise will elevate the firm's robust consultative offerings across a number of verticals, including technology, consumer products, financial services, private equity and venture capital and life sciences.

Key Points: 
  • Kelley joins Nexus as a cross-functional global leader who brings operational and executive-level insights to the Charlotte-based firm.
  • As the founder of Sage&Sea Ventures, Kelley is an active angel investor and advisor for bioscience and human resources tech/talent start-ups led by diverse founders.
  • His perspective and passion for leveling the playing field for underestimated talent – particularly veterans – and creating opportunities at the executive level align seamlessly with Nexus' core values.
  • My life's work parallels Nexus' mission to create opportunities for diverse leaders at the executive level, and I'm excited to spark candidate-centric, systemic change in the executive search industry."

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

Retrieved on: 
Wednesday, January 10, 2024

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn't just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1's reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer's and Parkinson's to drug addiction, clinical trials are painting a stunning picture of GLP-1's versatility. And it doesn't stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Company (NYSE: LLY), Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WW), that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.

Key Points: 
  • GLP-1 agonists are among the hottest drugs in healthcare, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Lexaria Bioscience has developed DehydraTECH drug-delivery platform, which is being shown to improve pharmacokinetics of orally administered drugs.
  • Lexaria issued final data from the pilot study and is planning for multiple human and animal studies early in 2024.
  • Uncontrolled blood sugar dramatically increases the risk of devastating comorbidities, including kidney disease, vision loss, amputations, heart attacks, strokes and early death.

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

Retrieved on: 
Wednesday, January 10, 2024

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn't just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1's reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer's and Parkinson's to drug addiction, clinical trials are painting a stunning picture of GLP-1's versatility. And it doesn't stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Company (NYSE: LLY), Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WW), that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.

Key Points: 
  • GLP-1 agonists are among the hottest drugs in healthcare, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Lexaria Bioscience has developed DehydraTECH drug-delivery platform, which is being shown to improve pharmacokinetics of orally administered drugs.
  • Lexaria issued final data from the pilot study and is planning for multiple human and animal studies early in 2024.
  • Uncontrolled blood sugar dramatically increases the risk of devastating comorbidities, including kidney disease, vision loss, amputations, heart attacks, strokes and early death.

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs

Retrieved on: 
Monday, January 8, 2024

NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent research. Obviously, diabetes remains a primary indication, given the massive global need. However, the impact of this extraordinary molecule extends far beyond type 2 diabetes. The reach of GLP-1 drugs has widened in ways its inventors likely never imagined. Clinical trials are underway testing GLP-1 drugs to treat Alzheimer's, Parkinson's, and even drug addiction, plus there are strong indications of therapeutic efficacy in heart disease and chronic kidney disease, as well as a wide range of other conditions, including weight loss. The newfound applications of this super-drug re-enforce both the reach and impact of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile). By supercharging GLP-1 drugs with its DehydraTECH(TM) drug-delivery formulation and processing technology, Lexaria intends to improve both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. With several key studies on the near-term horizon, Lexaria has positioned itself in the midst of these market opportunities alongside others changing the landscape, such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Novo Nordisk (NYSE: NVO).

Key Points: 
  • GLP-1 agonists are the hottest drugs in healthcare today, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Similarly, product sales for obesity drugs are forecast to reach $100 billion within a decade, and the most promising drugs at the head of the pack are GLP-1 agonists.
  • Novo Nordisk (NYSE: NVO) , the owner of Ozempic(R), Rybelsus(R), Victoza(R) and Wegovy(R), is a world leader in diabetes and GLP-1 drugs.
  • Companies that enhance efficacy and expand usage could prove to be the biggest winners in the progression of GLP-1 drugs.